Kymera Therapeutics, Inc. Stock Price, News & Analysis

Kymera Therapeutics (NASDAQ: KYMR) announced its participation in the virtual 39th Annual J.P. Morgan Healthcare Conference scheduled for January 14, 2021. Nello Mainolfi, Co-Founder and CEO, will discuss the company’s advancements and expected milestones for 2021 at 2:00 p.m. ET. A live webcast will be available on the company’s website, with an archived version accessible for 90 days. Kymera focuses on targeted protein degradation to treat immune-inflammatory diseases and cancers, utilizing its Pegasus™ platform to harness the body’s natural processes.

Kymera Therapeutics (NASDAQ: KYMR) has appointed William Leong, PhD, as Vice President of Chemistry, Manufacturing and Controls (CMC), and Paul Cox as Vice President of Investor Relations and Communications. These strategic hires are expected to bolster the company’s operational capabilities as it approaches clinical development. Leong brings over 30 years of drug development experience, while Cox has 15 years in investor relations. Kymera aims to advance targeted protein degradation therapies to address complex disease targets using its proprietary Pegasus™ platform.

Kymera Therapeutics (NASDAQ: KYMR) presented preclinical data on its IRAKIMiD and STAT3 protein degrader programs at the virtual 62nd ASH Annual Meeting. The IRAKIMiD candidate KT-413 showed significant anti-tumor activity in MYD88-mutant DLBCL models and is poised for a Phase 1 trial in 2H 2021. Additionally, the STAT3 degrader KTX-201 demonstrated potent cell killing in lymphoma models. These developments indicate promising next steps for advancing targeted therapies for severe blood cancers.

Kymera Therapeutics (NASDAQ: KYMR) announced that its Co-Founder, President, and CEO Nello Mainolfi, along with Chief Medical Officer Jared Gollob, will present at the Piper Sandler 32nd Annual Healthcare Conference taking place virtually from December 1 to December 3, 2020. A pre-recorded fireside chat will be available for viewing, accessible via the company's website. Kymera focuses on targeted protein degradation, aiming to develop treatments for immune-inflammatory diseases and cancers by utilizing the body’s protein recycling mechanisms.

Kymera Therapeutics (NASDAQ: KYMR) will be featured at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 8:00 a.m. ET. Nello Mainolfi, the Co-Founder, President, and CEO, will present the company’s innovative approach to targeted protein degradation.

This biopharmaceutical company focuses on harnessing the body's protein degradation system to develop treatments for immune-inflammatory diseases, hematologic malignancies, and solid tumors. A live webcast of the presentation can be accessed on their website, with an archived version available for 90 days.

Kymera Therapeutics (NASDAQ: KYMR) has reported significant advancements in its targeted protein degradation pipeline and financial results for Q3 2020. The company completed a successful IPO, raising approximately $213.3 million, and formed a strategic collaboration with Sanofi worth up to $2 billion. Positive interim results from a study on KT-474 (an IRAK4 degrader) in HS patients were also presented. The company aims to file IND applications for KT-474 and KT-413 (IRAKIMiD degrader) in 2021, while maintaining a strong cash position of $481.3 million, ensuring operational funding through 2025.

Kymera Therapeutics (NASDAQ: KYMR) announced the presentation of new preclinical data for its IRAKIMiD and STAT3 degrader programs at the 62nd American Society of Hematology Annual Meeting from December 5-8, 2020. Key findings include KT-413's efficacy in MYD88-mutant DLBCL models, showing deep tumor regressions with intermittent dosing. The STAT3 program also demonstrated tumor regressions in ALK+ ALCL. These results highlight the therapeutic potential of Kymera's targeted protein degradation approach to treat hematologic cancers effectively.

Kymera Therapeutics (NASDAQ: KYMR) is set to present key findings at the 3rd Annual Targeted Protein Degradation Summit on Oct. 14 and 15. CEO Nello Mainolfi will deliver a keynote on the IRAK4 program and its role in treating conditions like hidradenitis suppurativa (HS) and atopic dermatitis (AD). The company emphasizes its innovative Pegasus platform, showcasing preclinical studies on pharmacokinetic/pharmacodynamic (PK/PD) relationships essential for clinical drug development. Significant results include elevated IRAK4 levels in diseased skin, highlighting the pathway's relevance in HS.

Kymera Therapeutics (NASDAQ: KYMR) presented interim data at the 5th Annual Symposium on Hidradenitis Suppurativa Advances, revealing insights from a non-interventional trial on IRAK4 expression in patients with hidradenitis suppurativa (HS) and atopic dermatitis (AD). The study highlighted the effectiveness of KT-474, an IRAK4-targeted protein degrader, in lowering IRAK4 levels in blood mononuclear cells. With a Phase 1 trial expected to start in 2021, these findings support the potential of IRAK4 degraders in treating HS and other inflammatory diseases, addressing a critical unmet medical need.